

USE OF BLACK SEED (*NIGELLA SATIVA* L.) OIL IN THE MANAGEMENT OF HYPERTENSIVE AND HYPERLIPIDEMIC INDIVIDUALS OF DISTRICT MUZAFFARABAD, AZAD KASHMIR, PAKISTAN

HUSSAIN, N.¹ – MAJID, S. A.¹ – ABBASI, M. S.² – HUSSAIN, M. A.^{*3} – REHMAN, K.⁴ – KHAN, M. Q.¹ – DAR, M. E. U. I.¹ – SHAHEEN, H.¹ – HABIB, T.¹

¹Department of Botany, University of Azad Jammu & Kashmir
Muzaffarabad 13100, Pakistan

²Department of Cardiology, Abbass Institute of Medical Sciences
Muzaffarabad 13100, Pakistan

³Department of Biotechnology, Mirpur University of Science & Technology (MUST),
Mirpur-10250, AJK, Pakistan

⁴Department of Botany, Mirpur University of Science & Technology (MUST),
Mirpur-10250, AJK, Pakistan

*Corresponding author
e-mail: scholar.ataf@gmail.com

(Received 19th Nov 2016; accepted 21st Mar 2017)

Abstract. Hypertension and hyperlipidemia are two main causes of cardiovascular diseases with rapidly increasing pervasiveness worldwide. Complimentary alternative medicines provide an effective choice to these highly prevalent global health issues. *Nigella sativa* has diverse range of traditional and pharmacological potential with established safety profile. This study was carried out in 163 mild-moderate hypertensive and hyperlipidemic patients. Patients were selected randomly of both genders. The patient's age ranges between 20-65 years. This clinical study was conducted to evaluate the clinical effect of *Nigella sativa* virgin oil in hypertension and hyperlipidemic patients of the selected region and also assess its antioxidant potential. The results conferred that *N. sativa* has significant (< 0.05) effect on controlling hypertension and hyperlipidemia as compared to standards used. Moreover, *N. sativa* conferred excellent antioxidant potential as compared to other commercially available edible oils.

Keywords: alternative medicines, pharmacological, antioxidants, virgin oil, edible oils

Introduction

Hypertension is the major cause of cardiovascular diseases (CVD) which is significantly increasing day by day and according to an estimate by the end of 2025 it will go up to 1.4 billion of the world's adult population (Kearney et al., 2005). Hypertension is defined as a systolic blood pressure greater than 140 mmHg and/or diastolic 90 mmHg or greater, and any record of serum lipid abnormality is defined as hyperlipidaemia. There are number of known cardiovascular disease, renal disease, liver disease, obesity, high cholesterol and stressful conditions; an unknown reasons of high blood pressure (essential hypertension). Hypertension is a silent killer disease as it may go undiagnosed for years and when detected had developed chronic heart disease, cardiovascular disease, diabetes mellitus, renal disease, etc. However, if properly diagnose and treat would reduce the morbidity and mortality (Schuman and Emerson, 1998). Hypertension in long terms impairs the renal function and resulted to failure in

majority of the cases (Klag et al., 1996) and these all causes cardiovascular complication (Rostand et al., 1991). Clinical studies demonstrated that a reduction in hypertension can control 42% risk of stroke and 14% coronary heart disease (Hobbs, 2004). In the struggle of modernization and exposure to globalization the population of low income countries greatly affected their lives to pursue their high living standards. Although some get well succeed status but many deprived in hands of cultural and social adjustments that may cause increase in hypertension. Hypertension has long been thought of Western world disease but now it is equally the part of poor countries. In addition to organic causes lifestyle play major role in this regard. The lifestyle of many people has become more westernized. Several studies hypothesized its contribution to hypertension in urban populations when compared to rural populations (Ma et al., 2012). Within the non-communicable diseases hypertension plays leading role posing threats of disabilities (WHO, 2013) and this is because of unawareness to these conditions by a high number of hypertensive individuals (Kayima et al., 2013). In a study of prevalence of hypertension, in low and middle income countries the blood pressure found in more than half of population higher than in US (Fuentes et al., 2000). Although hypertension is the cause of mortality and morbidity in world (Rodger et al., 2004) but stroke in urban East-African countries is five times higher than in Britain (Walker et al., 2000).

Nigella sativa is an annual herb belonging to family *Ranunculaceae* with huge medicinal potential. Its seeds and seeds extracts has been used medicinally for centuries especially in Mediterranean region, Middle-East and Southeast Asia (Rchid et al., 2004; Najmi, et al., 2008). It has tremendous traditional and pharmacological potential in curing a wide range of ailments particularly hypotension (Aqel, 1992), hypoglycaemia (Bamosa et al., 1997; Meral et al., 2001; Bamosa et al., 2010), oxidative stress (Burits and Bucar, 2000) and cardio protective (Tasawar et al., 2011). *N. sativa* plant has strong antihypertensive effect that significantly lowered down blood pressure and cholesterol (Dehkordi and Kamkhah, 2008). Reinhart et al. (2008) also reported its hypotensive, hypercholesterolemic, hypoglycaemic and antioxidative activities. *N. sativa* significantly reduces intracellular cholesterol by regulating LDL, HDL and triglycerides blood levels (El-Dakhakhany, 2000). Obesity is the main cause of metabolic syndrome (Vega, 2001). BMI is also an important indicator of metabolic syndrome (Najmi et al., 2008). *N. sativa* showed a significant reduction in the body weight when administered to a experimental model of rats (Zaoui et al., 2002). More than 100 bioactive compounds had been reported in the *N. sativa* seeds (Ramadan, 2007). The therapeutic potential of medicinal plants is mainly due to the antioxidative properties of some active components (El-Saleh et al., 2004). The seeds of *N. sativa* contains two active components in its oils i.e. Thymoquinone and dihydrothymoquinone, revealed enormous potential of free radical scavenging capabilities (Khalife and Lupidi, 2007). These biological active compounds considered largely as chemo protective (Badary et al., 1999 and Badary et al., 2007), gastro protective (El-Abhar et al., 2003; Kanter et al., 2005) and immuno protective (Gilani et al., 2004). The foods rich in fats after absorption through intestine intensify the hepatic detoxification, enhance lipid peroxidation and resulted debris cause cellular modifications. Cholesterol in the blood vessels also constructs fibrosis plaque along the walls. These plaques are atherosclerotic proliferation of the extra cellular matrix formed due to extensive biochemical and molecular changes within the vessels (Glass and Witztum, 2001; Tiwari et al., 2008). Oxidation by free radicals is an imperative incident cause aging and human diseases.

The antioxidant screening of plants and their phytochemicals through comparing commercial antioxidants could help to find new source of expected innate antioxidants. *N. sativa* and its active components have tremendous potential of nutraceutical and pharmaceutical applications. This needs to be explored through more clinical studies in metabolic syndrome that is the challenge of future to medical professionals. The present study was undertaken to explore probable antioxidant potential of *N. sativa* found in its different parts which is responsible for lowering high blood pressure, serum cholesterol and plasma sugar. The data on the evaluation of *N. sativa* clinically and as antioxidant are scanty. This was the first ever study for validating the therapeutic potential of *N. sativa* in the state of Azad Kashmir, Pakistan.

Methodology and Materials

Patient Selecting Criterion

Patients with mild-moderate hypertension were selected from outpatient departments (OPD) of Abbass Institute of Medical Sciences (AIMS) Muzaffarabad and from medical camps organized through AIMS cardiology department. Before starting the study an approval from hospital ethical committee was taken. After explaining all the outcomes of the treatment and taken written consent from all participants (*Supplementary Figure 3*), pathological history was recorded through questionnaire (*Supplementary Figure 1*). During selection every aspect of patient interest focussed so that satisfies his convenience in perfection of better compliance. A total of 180 patients were registered for this clinical study which was divided in to two groups, each comprising 90 individuals. All patients were selected from the same geographical area randomly with a male and female ratio of 43:57. Selection of Patients were based on category, Mild-Moderate Hypertension, Systolic Blood Pressure 130-159 mmHg; Diastolic Blood Pressure 80-99 mmHg, Abdominal obesity (Waist circumference): >102 cm in males and >88 cm in females, Total Cholesterol: ≥ 200 mg/dL, Serum Triglycerides: > 150 mg/dL, LDL: > 120 mg/dL, HDL: < 40 mg/dl (male) or HDL < 50 mg/dL (female). Serum Glucose: ≥ 110 mg/ dL.

Patient's weight and height were measured for Body Mass Index calculation BMI (Kg/m^2). Patient's systolic and diastolic blood pressure was recorded by using mercury Sphygmomanometer (Tycos Japan). Fasting blood samples (Venus) were taken in the hospital pathological laboratory and analysed for all biochemical tests using principal biochemistry analyzer and enzyme assays. Adverse events report proformas (*Supplementary Figure 2*) to report any adverse event and laboratory proformas (*Supplementary Figure 4*) to file all base line tests reports were prepared. A copy of each was given to patient for record. Patients were divided randomly including male and female's age ranged from 20-65 years into *N. sativa* and standard statin groups. One group was started with *N. sativa* oil treatment while second on statin standard treatment (atorvastatin 10 mg tablet once a day) and metformin 500 mg tablet one twice a day added to diabetics after taking a baseline data of all biochemical parameters. All the patients were strictly advised to follow the guide lines regarding physical activities, diet and maintained it regularly in routine life style. *N. sativa* seeds virgin oil (NsVO) administered orally twice a day in a dose of 0.5 ml before breakfast and going to bed for sleeping at night. During the study period patients were closely monitored through telephone calls, personal visits and every fortnight calls on hospital visits for blood

pressure examination. After 45 days patient's blood samples taken in the hospital pathological laboratory and data were analyzed statistically by using paired t-test.

The Antioxidant Assay

Antioxidant potential of *N. sativa* and edible oils was evaluated by using free radical scavenging DPPH assay (2,2-diphenyl-1-picrylhydrazyl) as described by Amarowicz et al. (2004). The absorbance was recorded at 517 nm through ultrospec-4000 (Pharmacia-LKB) UV-visible spectrophotometer. The radical scavenging activity was expressed as IC₅₀. Ascorbic acid was used as standard. The percentage scavenging activity was calculated by using the following formula:

$$\text{Percentage Inhibition} = \frac{(\text{A control} - \text{A extract})}{(\text{A control})} \times 100$$

where A control is the absorbance of the control reaction, A extract is the absorbance of the test sample.

Results and Discussion

The study was undertaken with the aim to compare the antihypertensive and antihyperlipidemic effect of *N. sativa* virgin oil and standard statin treatments with their respective baseline data's in selected area. For this purpose 180 patients was screened out. Out of 180 patients 163 comply while 17 did not due to personal reasons. Statistical analysis showed that *N. sativa* has significant (P-value = < 0.05) effect on controlling hypertension (Systolic Bp P=3.079e-07; Diastolic Bp P=2.136e-06) and hyperlipidemia (Total cholesterol P = 2.2e-16, LDLc P = 2.2e-16, HDLc P = 4.739e-12 and TGs P = 0.05706) as compared to standard group (Systolic Bp P=5.505e-07; Diastolic Bp P = 1.005e-07; Total cholesterol P = 4.805e-13, LDLc P = 4.803e-10, HDLc P = 4.049e-06 and TGs P = 1.441e-07) through its antioxidative activities (Table 4, 5). The patients receiving *N. sativa* treatment after 45 days the mean systolic (154.35 mmHg) and diastolic (95.20 mmHg) blood pressure at baselines was reduced to 142.80 mmHg and 88.15 mmHg respectively (Table 1; Fig. 1, 3). Among the 83 patients 59 (71%) showed a significant decreased in blood pressure, 13 (16%) increased and 11 (13%) showed no effect of the treatment (Fig. 2). In comparison to the 2nd group of standard treatment after 45 days the mean systolic (153.60 mmHg) and diastolic (95.18 mmHg) blood pressure at baselines was also reduced to 146.60 mmHg and 90.30 mmHg respectively (Table 1, Fig. 4) but it was less than *N. sativa* group. Among the 80 patients receiving standard treatment 46 (57%) showed a decreased in blood pressure, 16 (20%) increased and 18 (23%) showed no effect of the treatment (Fig. 3). The percent effect of *N. sativa* (71%) at individual levels was also better compared to standard group (57%). Various traditional and animal studies report the promising hypotensive action of the seeds and extracts of *N. sativa*. Rahman et al. (1990) described the antihypertensive effect of the methanolic seeds extracts of *N. sativa* in the normal and adrenaline induced hypertension. Dehkordi and Kamkhah (2008) suggested that 200 mg *N. sativa* seeds extract twice daily for 8 weeks significantly lowered down the systolic and diastolic blood pressure.




Figure 1. Mean comparison of *N. sativa* patients vs. standard statin at baseline after 45 days treatment




Figure 2. Pattern of systolic and diastolic blood pressure of the individuals after *N. sativa* treatment at baseline




Figure 3. Pattern of systolic and diastolic blood pressure of the individuals after standard treatment at baseline

The *N. sativa* treatment showed a considerable reduction in the total cholesterol (~218-205 mg/dl), LDLc (~135-122 mg/dl) and triglycerides (~204-194 mg/dl) levels at their baselines as compared to the standard treatment which were ~222-215 mg/dl, ~136-130 mg/dl and ~190-180 mg/dl respectively. There was found a significant

reduction in the mean total cholesterol ($P = 2.2e-16$) and LDLc ($P = 2.2e-16$) in *N. sativa* group as compared to standard group ($P = 4.805e-13$ and $P = 4.803e-10$). The effect of seeds extract in animal model (for 12 weeks) has been evaluated by Zaoui et al. (2002) which showed a decrease in the levels of cholesterol, triglycerides and blood glucose. Dekhordi and Kamkhah (2008) depicted that 100 or 200 mg twice daily doses of *N. sativa* significantly reduced the total and LDL cholesterol in a dose dependent manner. Pourghassem-Gargari et al. (2009) and Nader et al. (2010) reported that if black seeds used in diet supplements can effectively decrease the total cholesterol (43.7 %), LDLc (42.8 %) and TGs (34.9 %) after one month of treatment as compared to control. The improvement in HDLc is although low (37.7-39.50 mg/dl), however better than in case of standard therapy (39.18-39.5 mg/dl). The results are in agreement reported by Najmi et al. (2008) and Le et al. (2004).

Reduction in BMI has positive effect on obesity. The treatment with *N. sativa* showed the reduction of BMI (26.22-25.52 kg/m²) as compared to standard group (27.90-27.38 kg/m²) however waist in both cases (~92-91 and ~98-97 cm) were comparable (Table 1). The reduction in triglyceride levels were also found same in both groups (204-194 mg/dl and 190-180 mg/dl). Similar results were reported by Najmi, et al. (2008) while working with *N. Sativa*. Datau et al. (2010) found a reduction in the body mass index when used *N. sativa* seeds in a dose of 1.5 g/day for three months in obese individuals. Although their study conferred that the reduction in BMI and waist was not much significant but it had good impact on improving cholesterol. Moreover, In the *N. sativa* group the HDLc was raised 37.73-39.50 mg/dl while in standard group the value was 39.18-39.50 mg/dl which showed a significant ($P = 4.739e-12$) augment due to the *N. sativa* treatment. It has also been observed the high impact of the *N. sativa* treatment on the reduction of fasting blood glucose levels (~150-128 mg/dl) in comparison to the standard treatment (~147-144 mg/dl) at baseline (Table 1; Fig. 4, 5). The studies of Bamosa et al. (2002) and Najmi, et al. (2008) also supported the findings of the present study on total cholesterol, LDL, HDL, Triglyceride and fasting blood sugar.

Table 1. Mean comparison of *N. sativa* vs. standard treatment at their respective baselines

Biochemical Parameters	Control vs. NsVO		Control vs. Statin	
	Before Treatment Means Value	After Treatment Means Value	Before Treatment Means Value	After Treatment Means Value
Systolic Bp (mmHg)	154.35	142.80	153.60	146.60
Diastolic Bp (mmHg)	95.20	88.78	95.18	90.30
BMI (Kg/m ²)	26.22	25.52	27.90	27.38
Waist (cm)	92.00	91.33	98.00	97.13
T. Cholesterol (mg/dl)	218.25	204.80	221.65	215.13
LDL (mg/dl)	134.63	122.10	135.75	130.10
HDL (mg/dl)	37.73	39.50	39.18	39.50
Triglycerides (mg/dl)	203.70	193.73	189.80	180.23
BSF (mg/dl)	149.73	128.54	146.73	143.92




Figure 4. Mean comparison of *N. sativa* patients vs. base line after 45 days treatment




Figure 5. Mean comparison of standard vs. baseline after 45 days treatment

Furthermore, when cholesterol and sugar levels were undertaken resulted lowered down along with blood pressure which also controlled due the fact that an increase in blood pressure found to be linked with increased cholesterol and sugar levels (Siok-Koon et al., 2009). The systolic and diastolic blood pressure significantly lowered down with the increased in duration of the *N. sativa* treatment. The systolic blood pressure was decreased to ~134 mmHg after 90 days and ~127 mmHg after 180 days of *N. sativa* treatment at baseline of ~155 mmHg followed by decrease in diastolic blood pressure as ~83 mmHg and ~76 mmHg after 90 and 180 days at baseline of ~94 mmHg respectively (Table 2; Fig. 6). In case of standard treatment the systolic (~153 mmHg) blood pressure was decreased to ~145 and 138 mmHg after 90 and 180 days while the diastolic (~94 mmHg) was decreased to ~90 and ~84 mmHg after 90 and 180 days respectively (Table 3; Fig. 7). Similarly patients receiving *N. sativa* showed a remarkable reduction in the mean total cholesterol, LDLc and triglycerides with the increase in HDLc after six month of treatment. The *N. sativa* group significantly reduced the cholesterol (199 and 186 mg/dl), LDLc (113 and 99 mg/dl), triglyceride (168 and 154 mg/dl) and fasting blood sugar (112 and 94 mg/dl) after 90 and 180 days of treatment at baselines of 220 mg/dl, 136 mg/dl, 191 mg/dl and 150 mg/dl respectively. The HDLc was increased to 40.80 mg/dl and 42.13 mg/dl at the baseline of 39.05 mg/dl after 90 and 180 days of *N. sativa* treatment respectively (Table 2; Fig. 6).

Table 2. Mean comparison of *N. sativa* group after 45, 90 and 180 days treatment at baseline

Biochemical Parameters	Control	After 45 Days	After 90 Days	After 180 Days
Systolic Bp (mmHg)	155.07	142.80	134.18	127.28
Diastolic Bp (mmHg)	94.3	88.78	83.23	76.35
BMI (kg/m ²)	26.65	25.52	25.93	25.55
Waist (cm)	91.75	91.33	90.15	89.13
T. Cholesterol (mg/dl)	219.7	204.80	198.53	186.03
LDL (mg/dl)	135.9	122.10	112.70	99.20
HDL (mg/dl)	39.05	39.50	40.80	42.13
Triglycerides (mg/dl)	190.8	193.73	168.00	154.25
BSF (mg/dl)	149.73	128.54	111.73	93.73




Figure 6. Mean comparison of *N. sativa* group after 45, 90 and 180 days treatment at baseline

Table 3. Mean comparisons of standard group after 45, 90 and 180 days treatment at baseline

Biochemical Parameters	Control	After 45 Days	After 90 Days	After 180 Days
Systolic Bp (mmHg)	153.15	146.60	145.0	137.8
Diastolic Bp (mmHg)	95.15	90.30	90.15	84.25
BMI (kg/m ²)	27.48	27.38	26.89	26.53
Waist (cm)	96.65	97.13	95.8	95.1
T. Cholesterol (mg/dl)	226.95	215.13	218.4	210.07
LDL (mg/dl)	137.27	130.10	126.8	121.15
HDL (mg/dl)	38.75	39.50	39.82	40.67
Triglycerides (mg/dl)	195.07	180.23	178.22	159.57
BSF (mg/dl)	146.73	143.92	127.08	129.27




Figure 7. Mean comparisons of standard group after 45, 90 and 180 days treatment at baseline

Table 4. Comparison of variables before and after *N. sativa* treatment using paired *t*-test

Variables of <i>N. sativa</i> Group	T-values	DF	P-values	95% Confidence Interval	Remarks
Systolic Bp (mmHg)	5.57	82	3.079 e-07	5.656962 11.933400	Significant
Diastolic Bp (mmHg)	5.10	82	2.136 e-06	3.123754 0.4335806	Significant
BMI (Kg/m ²)	9.57	82	5.284 e-15	0.6611182 0.6967115	Significant
Waist (cm)	5.56	82	3.215 e-07	1.4719632 9.130463	Significant
T.Cholesterol (mg/dl)	11.12	82	2.200 e-16	13.110501 9.072539	Significant
LDL (mg/dl)	11.015	82	2.200 e-16	13.072039 0.8538746	Significant
HDL (mg/dl)	8.085	82	4.739 e-12	1.4111856 -0.1847185	Significant
TG (mg/dl)	1.93	82	0.05706	12.2088148	Insignificant

Table 5. Comparison of variables after and before standard treatment using paired *t*-test

Variables of Standard Group	T-values	DF	P-values	95% Confidence Interval	Remarks
Systolic Bp (mmHg)	5.4524	79	5.505 e-07	3.97632 8.54868	Significant
Diastolic Bp (mmHg)	5.8629	79	1.005 e-07	2.617235 5.307765	Significant
BMI (Kg/m ²)	0.9611	79	0.3394	-0.2577192 0.7389692	Insignificant
Waist (cm)	5.0999	79	2.279 e-06	0.4725213 1.0774787	Significant
T. Cholesterol (mg/dl)	8.6449	79	4.805 e-13	4.464578 7.135422	Significant
LDL (mg/dl)	7.1002	79	4.803 e-10	4.039113 7.185887	Significant
HDL (mg/dl)	4.9542	79	4.049 e-06	0.2392906 0.5607094	Significant
TG (mg/dl)	5.7769	79	1.441 e-07	5.866225 12.033775	Significant

The systolic and diastolic Bp significantly (P-value = < 0.05) decreased when treatment of *N. sativa* was continued for another 45 days. The systolic and diastolic blood pressure was raised from ~143-148 mmHg and ~88-94 mmHg respectively when that group of patients was treated with placebo however, the total cholesterol was increased from ~200-209 mg/dl and LDLc ~102-125 mg/dl while no significant change was recorded in the levels of HDLc and triglycerides. Moreover a little change conferred in BMI (25.52-25.33 kg/m²) and waist circumference (91.32-90.12 cm) while blood sugar was raised from 128 – 146 mg/dl (Table 6).

Table 6. Comparison of variables before and after placebo treatment using paired t-test

Variables of Placebo Group	T-values	Degree of freedom	P-values	95% Confidence Interval	Remarks
Systolic Bp (mmHg)	2.6223	39	0.01239	1.126098 8.723902	Significant
Diastolic Bp (mmHg)	4.5873	39	4.562e-05	3.032939 7.817061	Significant
BMI (kg/m ²)	3.2084	39	0.002669	0.04517891 0.19932109	Significant
Waist (cm)	-1	39	0.3235	-0.15113455 0.05113455	Insignificant
T.Cholesterol (mg/dl)	5.8299	39	8.924×10 ⁻⁰⁷	4.163177 8.586823	Significant
LDL (mg/dl)	5.4011	39	3.509e-06	8.897783 19.552217	Significant
HDL (mg/dl)	2.6234	39	0.01236	-0.26565178 - 0.03434822	Significant
TG (mg/dl)	1.1905	39	0.241	-1.799843 6.949843	Insignificant
BSF (mg/dl)	6.9145	25	3.011e-07	12.42255 22.96206	significant

The antioxidant activity of the extracts of all lines of *N. sativa* was assessed by using DPPH assay and IC₅₀ value recorded was tabulated in Table 7. Among seven lines tested, the N1 sample was found to be potent (Table 7; Fig. 8). When compared different solvents extracts, the ethyl acetate was found to be a potent solvent for the extraction of potential compound with IC₅₀ values for N1 (0.0022), N2 (0.0033), N3 (0.0030) and N7 (0.4476) while methanol, chloroform and acetone extracts showed least activity (Table 7; Fig. 8). Due to the factual antioxidant potential of seeds of *N. sativa*, a detail screening of all parts was carried out. Here also the N7 line was found to be potent. The IC₅₀ value recorded for ripen seeds was 0.000415 followed by unripe (green seeds) i.e. 3.510731 as compared to the standard used (Table 8; Fig. 9a and 3c). Other parts were found to be rubbished (Table 8; Fig. 9b). Vinha et al. (2005) reported that variation in antioxidant potential among all parts of same genotype was due to variation in secondary metabolites in different parts or may be due to extraction procedures, which is adopted for the extraction of active constituents. Commercially available edible oils were also screened with the purpose to compare their potential with selected genotype. It was found that *N. sativa* had great antioxidant potential as compared to the edible oils tested (Table 9; Fig. 9d). According to Skerget et al. (2005) sometime sampling of the same plant from the same ecological zone may deviate to the potential behavior because of mishandling of sampling procedures that could immediately oxidized the active metabolites and the antioxidant ability of the plants.

Yoruk et al. (2010) also reported significant antioxidant potential of *N. sativa* preventing oxidative stress by scavenging reactive oxygen species. The current results were in harmony with the previous studies.

In the present findings of clinical studies the use of *N. sativa* virgin oil (N7) revealed a significant reduction in the blood pressure and other biochemical parameters. The evidence from literature also supports the findings that the antioxidants protect the body against the development of atherosclerosis and provide putative hypotensive effects (Rohdewald, 2002; Paulis and Simko, 2007). Antioxidants contained melatonin (Flavonoids) can effectively be used in reducing blood pressure, lipid profile, body weight and plasma glucose (Hussein et al., 2007). Antioxidants have strong impact of reducing the blood pressure which is also supported by a recent study (Rezzani et al., 2010) that described the protective role of antioxidants against the initiation of atherosclerosis in hypertensive animal model. Houghton et al. (1995) reported that the biologically active constituents of *N. sativa* had potent quenching capabilities for free radicals. On the basis of present findings it is conferred that the poor antioxidant effects in treating various pathological conditions are more or less due to improper dosage, methods of extraction, selection of the seeds cultivar and the selection of the seeds lots. So it is suggested that only an intellectual approach could succeed in achieving the desired results while implementing any treatment of plant material consisting these oxidants. Moreover the oxidative stress promptly impregnate its harmful effects on the arterial vasculature that require long time to correct in a smoothly manner. Allopathic drugs although provide to some instant relieve to the inflammation of the endothelial linings of the vasculature but could not be the sole solution to the whole imploratory process of atherosclerosis.





Figure 8. Comparison of antioxidant activities of *N. sativa* seeds in four solvent extracts of seven lines in different concentrations and IC50 values

Conclusion


On the basis of the current investigations it is concluded that *N. sativa* seeds and oil should be considered routinely in the management of diabetic and hypercholesterolemic disorders as remedy was found to be potent hypotensive, antihyperlipidemic and hypoglycaemic with strong antioxidative activities without any adverse effect. *Nigella sativa* proved to be the best alternatives remedial source to cure these fatal ailments with

remarkable benefits of many other concomitant cures. However more investigations are needed to isolate bioactive compounds that are responsible of managing high blood pressure and other biochemical disorders.


Figure 1 (A): *Nigella sativa* oil VS standards



(B): *Nigella sativa* all parts



(C): Antioxidant potential of *Nigella sativa* all parts and Standard



(D): Antioxidant potential of *Nigella sativa* all lines and other edible oils




Figure 9. Antioxidant activities of *N. sativa* seeds oil VS standards (A), all parts (B), all parts VS standards (C) and all seven lines VS other edible oils

Table 7. Comparison of antioxidant activities of *N. sativa* seeds in four solvent extracts of seven lines in different concentrations and IC₅₀ values

Samples	Solvent	1 µl%	IC ₅₀
N1	Ethyl acetate	51.12	0.002266
N1	Acetone	25.89	4.199698
N1	Chloroform	27.45	5.0361
N1	Methanol	45.48	0.00217
N2	Ethyl acetate	68.99	0.00335
N2	Acetone	16.22	5.204309
N2	Chloroform	36.28	3.474909
N2	Methanol	59.79	0.00255
N3	Ethyl acetate	49.89	0.002035
N3	Acetone	29.94	4.721764
N3	Chloroform	30.69	8.978789
N3	Methanol	28.87	2.963774
N4	Ethyl acetate	51.04	3.859536
N4	Acetone	09.33	9.405586
N4	Chloroform	16.32	19.64961

N4	Methanol	16.00	5.326029
N5	Ethyl acetate	36.17	2.412749
N5	Acetone	21.43	6.666936
N5	Chloroform	25.99	5.312122
N5	Methanol	38.92	4.090206
N6	Ethyl acetate	53.18	2.721577
N6	Acetone	37.11	2.038345
N6	Chloroform	29.98	3.098866
N6	Methanol	47.00	7.267184
N7	Ethyl acetate	55.89	0.447679
N7	Acetone	28.65	0.003108
N7	Chloroform	21.08	4.366061
N7	Methanol	34.00	13.11741

Table 8. Antioxidant potential of all parts of *N. sativa* versus its five standards used

S. No.	Plant parts and Standards used	1 μ l	IC ₅₀
1	Stem	00.08	53.24247
2	Leaves	02.55	14.32170
3	Green Seeds	38.56	3.510731
4	Roots	00.01	165.3653
5	Ripened Seeds	65.08	0.000415
6	Milled Oil	59.89	0.000359
7	Thymol	03.66	25.75068
8	Thymoquinone	22.56	5.423880
9	t-Anethole	10.29	14.15704
10	Terpinen	00.03	16.88444
11	Carvacrol	02.11	24.97511

Table 9. Antioxidant activities of other edible oils available in the market and IC₅₀ values

Samples	Solvent	1 μ l _%	IC ₅₀
Oil	Sunflower	00.08	41.3329
Oil	Sesame	46.99	2.273876
Oil	Olive virgin	48.33	2.160575
Oil	Walnut	04.44	36.98957
Oil	Groundnut	00.01	7.588462
Oil	Grapes	00.91	25.44962
Oil	Mustard	23.76	62.50398

The beneficial effects of *N. sativa* in diabetic's subjects with fasting sugar, LDL, triglycerides, total cholesterol, BMI and high blood pressure were investigated and found highly significant ($P = < 0.05$) although the *N. sativa* was comparable to standards in short term but in longer therapy *N. sativa* revealed excellent role in controlling biochemical disorders. Maintaining serum glucose, serum cholesterol and high blood pressure at optimum reduces atherosclerosis and subsequently the risk of coronary heart diseases, a major threat to diabetic and hyperlipidemic patients. The potent antioxidative activities of *N. sativa* played a central role in functional optimization of biochemical parameters.

REFERENCES

- [1] Aqel, M. (1992): The relaxing effect of the volatile oil of *Nigella sativa* seeds on vascular smooth muscle. – Pure and Applied Sciences Series B 19: 91-100.
- [2] Amarowicz, R., Pegg, R. B., Rahimi-Moghaddam, P., Barl, B., Weil, J. A. (2004): Free-radical scavenging capacity and antioxidant activity of selected plant species from the Canadian prairies. – Food Chemistry 84(4): 551-562.
- [3] Badary, O. A., Al-Shabanah, O. A., Nagi, M. N., Al-Rikabi, A. C., Elmazar, M. M. (1999): Inhibition of benzopyrene-induced for stomach carcinogenesis in mice by thymoquinone. – European Journal of Cancer Prevention 8(5): 435-440.
- [4] Badary, O. A., Ellah, M. F., El-Mahdy, M. A., Salama, S. A., Hamada, F. M. (2007): Anticlastogenic activity of thymoquinone against benzopyrene in mice. – Food and Chemical Toxicology 45(1): 88-92.
- [5] Bamosa, A. O., Ali, B. A., Sowayan, S. A. (1997): Effect of oral ingestion of *Nigella sativa* seeds on some blood parameters. – Saudi Pharmacological Journal 5(2-3): 126-129.
- [6] Bamosa, A. O., Ali, B. A., Al-Hawsawi, Z. A. (2002): The effect of thymoquinone on blood lipids in rats. – Indian Journal of Physiological Pharmacology 46(2): 195-201.
- [7] Bamosa, A., Kaatabi, H., Lebda, F. M., Elq, A. M. A., Sultan, A. (2010): Effect of *Nigella sativa* Seeds on the Glycemic Control of Patients with Type 2 Diabetes Mellitus. – Indian Journal of Physiological Pharmacology 54 (4): 344-354.
- [8] Burits, M., Bucar, F. (2000): Antioxidant activity of *Nigella sativa* essential oil. – Phytotherapy Research 14(5): 323-328.
- [9] Datau, E. A., Wardhana, Surachmanto, E. E., Pandelaki, K., Langi, J. A. (2010): Efficacy of *Nigella sativa* on serum free testosterone and metabolic disturbances in central obese male. – Acta Medicina Indonesia 42(3):130-134.
- [10] Dehkordi, F. R., Kamkhah, A. F. (2008): Antihypertensive effect of *Nigella sativa* seed extract in patients with mild hypertension. – Fundamental & Clinical Pharmacology 22(4): 447-452.
- [11] El-Abhar, H. S., Abdallah, D. M., Saleh, S. (2003): Gastroprotective activity of *Nigella sativa* oil and its constituent, thymoquinone, against gastric mucosal injury induced by ischaemia/reperfusion in rats. – Journal of Ethnopharmacology 84(2-3): 251-258.
- [12] El-Dakhakhany, M., Mady, N. L., Halim, N. L. (2000): *Nigella sativa* Oil Protects against Induced Hepatotoxicity and Improves Serum Lipid Profile in Rats. – Arzneimittelforschung 50(9): 832-836.
- [13] El-Saleh, S. C., Al-Sagair, O. A., Al-Khalaf, M. I. (2004): Thymoquinone and *Nigella sativa* Oil Protection Against Methionine-induced Hyperhomocysteinemia in Rats. – International Journal of Cardiology 93(1): 19-23.
- [14] Fuentes, R., Ilmaniem, N., Laurikainen, E., Tuomilehto, J., Nissinen, A. (2000): Hypertension in developing economies: a review of population-based studies carried out from 1980 to 1998. – Journal of Hypertension 18(5): 521-529.
- [15] Gilani, A.H., Jabeen, Q., Khan, M. A. U. (2004). A review of medicinal uses and pharmacological activities of *Nigella sativa*. – Pakistan Journal of Biological Sciences 7(4): 441-51.
- [16] Glass, C. K., Witztum, J. L. (2001): Atherosclerosis: The Road ahead. – Cell 104(4): 503-516.
- [17] Houghton, P. J., Zarka, R., de las Heras, B., Hoult, J. R. (1995): Fixed oil of *Nigella sativa* and derived thymoquinone inhibit eicosanoid generation in leukocytes and membrane lipid peroxidation. – Planta Medica 61(1): 33-36.
- [18] Hussein, M. R., Ahmed, O. G. Hassa, A. F., Ahmed, M. A. (2007): Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: an animal model. – International Journal of Experimental Pathology 88(1): 19-29.

- [19] Hobbs, F. D. R. (2004): Primary Prevention of Cardiovascular Disease. Managing Hypertension and Hyperlipidaemia. – Heart 90: 22-25.
- [20] Kanter, M., Coskun, O., Korkmaz, A., Oter, S. (2005). Effects of *Nigella sativa* on oxidative stress and beta-cell damage in streptozotocin-induced diabetic rats. – Discoveries in Molecular, Cellular and Evolutional Biology Part A: The Anatomical Record 279(1): 685-691.
- [21] Kayima, J., Wanyenze, R. K., Katamba, A., Leontsini, E., Nuwaha, F. (2013): Hypertension awareness, treatment and control in Africa: a systematic review. – BMC Cardiovascular Disorders 13: 54.
- [22] Kearney, P. M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P. K., He, J. (2005): Global burden of hypertension: analysis of worldwide data. – Lancet 365(9455): 217-223.
- [23] Khalife, K. H., Lupidi, G. (2007). Nonenzymatic reduction of thymoquinone in physiological conditions. – Free Radical Research 41(2): 153-161.
- [24] Klag, M. J., Whelton, P. K., Randall, B. L., Neaton, J. D., Brancati, F. L., Ford, C. E., Shulman, N. B., Stamler, J. (1996): Blood pressure and end-stage renal disease in men. – The New England Journal of Medicine 334(1): 13-18.
- [25] Le, P. M., Benhaddou-Andaloussi, A., Elimadi, A., Settaf, A., Cherrah, Y., Haddad, P. S. (2004): The petroleum ether extract of *Nigella sativa* exerts lipid-lowering and insulin-sensitizing actions in the rat. – Journal of Ethnopharmacology 94(2-3): 251-259.
- [26] Ma, W. J., Tang, J. L., Zhang, Y. H., Xu, Y. J., Lin, J. Y. (2012): Hypertension prevalence, awareness, treatment, control, and associated factors in adults in southern China. – American Journal Hypertension 25(5): 590-596.
- [27] Meral, I., Yener, Z., Kahraman, T., Mert, N. (2001): Effect of *Nigella sativa* on glucose concentration, lipid peroxidation, anti-oxidant defence system and liver damage in experimentally-induced diabetic rabbits. – Journal of Veterinary Medicine A: Physiology, Pathology, Clinical Medicine. 48(10): 593-599.
- [28] Najmi, A., Nasiruddin, M., Khan, R. A. (2008): Effect of *Nigella sativa* oil on various clinical and biochemical parameters of insulin resistance syndrome. – International Journal of Diabetes in Developing Countries 28(1): 11-14.
- [29] Nader, M. A., El-Agamy, D. S., Suddek, G. M. (2010): Protective effects of propolis and thymoquinone on development of atherosclerosis in cholesterol-fed rabbits. – Archives of Pharmacal Research 33(4): 637-643.
- [30] Paulis, L., Simko, F. (2007): Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind. – Physiological Research 56(6): 671-684.
- [31] Pourghassem-Gargari, B., Ebrahimzadeh-Attary, V., Rafraf, M., Gorbani, A. (2009). Effect of dietary supplementation with *Nigella sativa* L. on serum lipid profile, lipid peroxidation and antioxidant defense system in hyperlipidemic rabbits. – Journal of Medical Plants Research 3(10): 815-821.
- [32] Rahman, M. S., Rafiquzzamn, M., Choudhury, S. A. R. (1990): Antihypertensive activity of *Nigella sativa*. – Traditional Medicine: 94-96.
- [33] Ramadan, M. F. (2007): Nutritional Value, Functional Properties and Nutraceutical Applications of Black cumin (*Nigella sativa* L.): An overview. – International Journal of Food Science Technology 42(10): 1208-1218.
- [34] Rchid, H., Chevassus, H., Nmila, R., Guiral, C., Petit, P., Chokaïri, M., Sauvaire, Y. (2004): *Nigella sativa* ex-tracts enhance glucose-induced insulin release from rat-isolated Langerhans islets. – Fundamental and Clinical Pharmacology 18(5): 525-529.
- [35] Reinhart, K. M., Coleman, C. I., Teevan, C., Vachhani, P., White, C. M. (2008): Effects of garlic on blood pressure in patients with and without systolic hypertension: a meta-analysis. – Annals of Pharmacotherapy 42(12): 1766-1771.
- [36] Rezzani, R., Porter, E., De Ciuceis, C., Bonomini, F., Rodella, L. F., Paiardi, S., Boari, G. E. M., Platto, C., Pilu, A., Avanzi, D., Rizzoni, D., Agabiti, R. E. (2010): Effects of melatonin and Pycnogenol on small artery structure and function in spontaneously hypertensive rats. – Hypertension 55(6): 1373-1380.

- [37] Rohdewald, P. (2002): A review of the French maritime pine bark extract (Pycnogenol), a Herbal medication with a diverse clinical pharmacology. – International Journal of Clinical Pharmacological Therapy 40(4): 158–168.
- [38] Rodgers, A., Ezzati, M., Vander Hoorn, S., Lopez, A. D., Lin, R.B., Murray, C. J. (Comparative Risk Assessment Collaborating Group) (2004): Distribution of major health risks: findings from the Global Burden of Disease study. – PLOS Medicine 1(1): e27.
- [39] Rostand, S. G., Brunzell, J. D., Cannon, R. O., Victor, R. G. (1991): Cardiovascular complications in renal failure. – Journal of American Society of Nephrology 2(6): 1053–1062.
- [40] Schumann, L., Emerson, B. (1998): Diagnostic evaluation for hypertension. – Journal of American Academy of Nurse Practitioners 10(6): 269–280.
- [41] Siok-Koon, Y., Lay-Gaik, O., Ting-Jin, L., Min-Tze, L. (2002): Antihypertensive Properties of Plant-Based Prebiotics. – International Journal of Molecular Sciences 10(8): 3517–3530.
- [42] Skerget, M., Kotnik, P., Hadolin, M., Hras, A. R., Simonic, M., Knez, Z. (2005): Phenols, proanthocyanidins, flavones and flavonols in some plant materials and their antioxidant activities. – Food Chemistry 89(2): 191–198.
- [43] Tasawar, Z., Siraj, Z., Ahmad, N., Lashari, M. H. (2011): The Effects of *Nigella sativa* (Kalonji) on Lipid Profile in Patients with Stable Coronary Artery Disease in Multan, Pakistan. – Pakistan Journal of Nutrition 10(2): 162–167.
- [44] Tiwari, R. L., Singh, V., Barthwal, M. K. (2008): Macrophages: An Elusive yet Emerging Therapeutic Target of Atherosclerosis. – Medicinal Research Reviews 28(4): 483–544.
- [45] Vega, G. L. (2001): Obesity, the metabolic syndrome, and cardiovascular disease. – American Heart Journal 142(6): 1108–1116.
- [46] Vinha, A. F., Ferreres, F., Silva, B. M., Valenta, P., Gonçualves, A., Pereira, J. A., Oliveira, M. B. P. P., Seabra, R. M. and Andrade, P. B. (2005): Phenolic profile of portuguese olive fruits (*Olea europaea* L.): influences of cultivar and geographical origin. Food Chemistry 89(4): 561–568.
- [47] Walker, R. W., Mc Larty, D. G., Kitange, H. M., Whiting, D., Masuki, G., Mtasiwa, D. M., Machibya, H., Unwin, N. and Alberti, K. G. (2000): Stroke mortality in urban and rural Tanzania. Adult morbidity and mortality project. – Lancet 355(9216): 1684–1687.
- [48] WHO. (2013): A global brief on Hypertension: silent killer, global public health crises (World Health Day 2013). – WHO, Geneva.
- [49] Yoruk, O., Gur, F. O., Uyanik, H., Yasar, M., Mutlu, V., Altas, E., Baysal, E. and Taysi, S. (2010): Antioxidant Effects of *Nigella sativa* in the Treatment of Experimentally Induced Rhinosinusitis. – Macedonian Journal of Medical Sciences 3(2): 132–137.
- [50] Zaoui, A., Cherrah, Y., Mahassini, N., Alaoui, K., Amarouch, H., Hassar, M. (2002): Acute and chronic toxicity of *Nigella sativa* fixed oil. – Phytomedicine 9(1): 69–74.

APPENDIX

Name of Participant			
Address			
Contacts			
Gender	☐ Male	☐ Female	☐ Age
Age Group	☐ 20-35yrs	☐ 36-50yrs	☐ 51-65yrs
Marital Status	☐ Single	☐ Married	☐ Divorced/Widow
Living Place	☐ Urban	☐ Rural	☐ Remote
Education	☐ Primary	☐ Secondary	☐ College
	☐ University		
Department	☐ Govt.	☐ Semi-Govt.	☐ Private
Occupation	Job Nature:		Position:
No. of Dependents	☐ 1-3 Persons	☐ 4-6 Persons	☐ 7-9 Persons
Exercise/activities	☐ 0 activity	☐ 1-1	☐ 2-2 ☐ 3-3
	☐ 4-4	☐ 5-5	
Diet Habit	☐ Normal	☐ Mix	☐ Fatty/Spicy
Living Environment	☐ Pleasant	☐ Tough	☐ Depressive
Job Environment	☐ Easy	☐ Compatible	☐ Stressed
Transportation	☐ Walking	☐ Public Transport	☐ Official Conveyance
Sleeping Habits	☐ Comfortable	☐ Delayed	☐ Difficult
Family Life	☐	☐	☐

Supplementary Figure 1. Questionnaire used for the subjects in clinical studies

<u>Registration for the Clinical Studies</u>	
I am explained all the benefits and outcomes of the treatment that will have to be given me during this clinical studies. I agreed voluntarily basis and promise to be loyal with all its treatment protocol.	
Name: _____	ID: _____
Male or Female: _____	Date of Birth: _____
Signature: _____	Contact #: _____
Witness: _____	
<u>Diagnosed Indications</u>	

<u>Responsible Clinician</u>	
Name: _____	Position: _____ Tel#: _____
Date: _____ Time: _____	

Supplementary Figure 2. Proforma used for subjects consent participating in clinical study

Serious Adverse Event Report			
If there is suspected any Serious Adverse Event (SAE) related to the treatment, register all the details in the Performa below and please call immediately 03455894220.			
<u>Responsible Clinician</u>			
Name: _____		Position: _____ Tel#: _____	
<u>Patient Details.</u>			
Pt. Name: _____		Date: _____ Time: _____	
Male or Female: _____		Patient ID: _____	
Treatment#: _____		Date of Birth: _____	
Allocated Date: _____		Dosage: _____	
Duration used: _____			
<u>Adverse Event Details</u>			
Event: _____			
Time & Date of onset:		End time and date:	
Mild to Moderate	Severe	Life Threatening	Hospitalization
Persistent or Recovered			
Other; _____ (Not covered by categories but, in the investigator opinion, should be considered serious).			
How you suspect the adverse event to be related to this treatment? _____			
How you rate this event treatment related from 0-100%			
Patient Name/Signature _____		Date: _____	

Supplementary Figure 3. Proforma used for subjects reporting serious adverse events

Clinical Investigations			
			Date: _____
1	Blood Pressure:	Systolic: _____	Diastolic: _____
(References)			
2	Lipid Profile:	Lower Limit	Upper Limit
Cholesterol: _____		3.6 mmol/l	6.5mmol/l
Triglyceride: _____		≤1.7mmol/l	≤1.7mmol/l
LDL: _____		2mmol/l	3.4mmol/l
HDL: _____		0.9mmol/l	2.2mmol/l
3	Serum Glucose:		
Random: _____		6.6mmol/l	10mmol/l
Fasting: _____		3.8mmol/l	6.1mmol/l
Creatinine Clearance: _____			
BMI: _____		Weight: _____	Waist: _____ Height: _____
Patient consent			
Do you agree for clinical trial? _____			
Name & Sig			

Supplementary Figure 4. Proforma used for subjects clinical investigations